| Antibodies - Kyushu University team develops antibody to fight age-related muscle atrophy |
|
|
|
|
| |
|
|
| |
The latest antibodies news from News Medical |
|
|
|
 | | |
 Download Now: Bispecific Antibodies Targeting Immunomodulatory Checkpoints for Cancer Therapy
Bispecific antibodies (BsAbs) revolutionize cancer therapy by enhancing immune responses and reducing side effects. Download ACRO's white paper on BsAbs targeting immunomodulatory checkpoints in cancer therapy. Discover how they surpass monoclonal antibodies, explore their design, mechanisms, and clinical progress, and uncover their potential to enhance precision, combat resistance, and reduce side effects, shaping the future of cancer treatment.
| |
|
|
|
|
| | |  The Golgi apparatus modifies, sorts and packages proteins to be sent to their final destinations, whether that's within or outside of the cell. | | | | |  One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. | | | | |  Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR T-cells. This breakthrough enhances tumor targeting while reducing off-target effects, paving the way for advanced synthetic biology applications. | | | | |  A simple dietary supplement may provide a new approach to boost CAR T cell function, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center. | | | | |  Thanks to CRISPR, our medical specialists will soon have unprecedented control over how they treat and prevent some of our most challenging genetic disorders and diseases. | | | | |  Fibroblastic reticular cells (FRCs) create T-cell-supportive niches within lung cancer tumors, facilitating T-cell migration, clustering, and activation. This study highlights FRCs' potential as therapeutic targets to boost anti-tumor immunity in non-small cell lung cancer (NSCLC). | | | | |  An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers. | |
|
|
|
|
| | | How would you rate today's newsletter?
| |
|
|
|
 | | |
 |
Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now. |
| |
|
|
|
|
|
